Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 1 · below the Ichimoku cloud · RSI 30 (oversold) · MACD above its signal
None of the 29 investors followed here reported a position in GCTK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a GCTK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 2, 2025 | Balo Andrew KDirector | — | 4.7K | — |
| Oct 2, 2025 | Carter Erin CatherineDirector | — | 1.4K | — |
| Oct 2, 2025 | Malave LuisDirector | — | 1.7K | — |
| Mar 25, 2025 | Balo Andrew KDirector | — | 4.5K | — |
| Mar 25, 2025 | Fischell Robert E.Director | — | 2K | — |
| Mar 25, 2025 | Danzig Allen EDirector | — | 1.8K | — |
| Mar 25, 2025 | Carter Erin CatherineDirector | — | 3.3K | — |
| Mar 25, 2025 | Ballantyne JohnDirector and Beneficial Owner of more than 10% of a Class of Security | — | 4.1K | — |
| Mar 25, 2025 | Malave LuisDirector | — | 3.2K | — |
| Mar 11, 2025 | Goode PaulChief Executive Officer | Conversion of Exercise of derivative security at price 31.20 per share. | 16.2K | $24.84K |
| Mar 11, 2025 | Carter Erin CatherineDirector | Conversion of Exercise of derivative security at price 31.20 per share. | 42.4K | $64.83K |
| Mar 11, 2025 | Ballantyne JohnDirector and Beneficial Owner of more than 10% of a Class of Security | — | 2.56M | — |
| Mar 11, 2025 | Malave LuisDirector | Conversion of Exercise of derivative security at price 31.20 per share. | 140.4K | $214.84K |
| Mar 11, 2025 | John A Ballantyne Revocable Living TrustTrustee | — | 2.56M | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -50.6 | -18.8 | -58.1 | 31.4 | -22.7 | -51.7 | 49.5 | -40.6 | -61.4 | -32.3 | −98.1% | ||
| 2025 | -82.8 | -71.8 | -51.5 | -1.1 | -24.9 | -23.1 | 2.5 | -31.4 | 56.2 | -1.8 | 5.1 | -43.1 | −99.1% |
| 2024 | -19.8 | 42.9 | 10.3 | 61.6 | -13.3 | -13.4 | -40.3 | 116.6 | -7.3 | -30.3 | -85.5 | 53.5 | −71.5% |
| 2023 | -8.5 | -6.6 | -71.8 | 23.5 | -4.5 | -14.0 | -8.4 | -17.7 | 1.2 | -31.6 | 30.6 | 11.5 | −81.4% |
| 2022 | -18.0 | -0.5 | 6.9 | -21.2 | -5.9 | -4.3 | -7.2 | -21.7 | 5.9 | -7.5 | -14.1 | -10.8 | −66.2% |
| 2021 | -7.0 | 3.0 | -16.2 | 22.8 | 0.0 | 17.1 | -2.4 | 17.3 | -4.9 | -19.8 | -24.7 | 19.1 | −9.6% |
| 2020 | -33.3 | -6.0 | 6.4 | 12.5 | -15.6 | -2.6 | -18.9 | -13.3 | 61.5 | -2.4 | -12.2 | -1.4 | −40.8% |
| 2019 | -10.4 | 9.4 | -49.0 | -8.0 | 13.0 | 15.4 | 40.0 | -4.8 | 0.0 | 10.0 | 68.2 | -18.9 | +20.0% |
| 2018 | -3.5 | -22.3 | 30.0 | 10.3 | -2.3 | -21.4 | 1.8 | -51.2 | 15.9 | -47.4 | -66.0 | 194.1 | −75.0% |
| 2017 | 4.0 | -25.0 | 0.3 | 2.3 | 12.5 | -11.1 | 5.0 | 71.4 | 18.1 | 5.9 | -8.7 | -51.3 | −20.0% |
| 2016 | 28.3 | -2.0 | -9.1 | 0.0 | 0.0 | -10.0 | -30.6 | 22.0 | -17.4 | 0.0 | 18.7 | -16.4 | −28.6% |
| 2015 | -16.7 | 0.0 | -2.0 | 53.1 | -33.3 | -10.0 | 8.9 | 17.3 | -30.4 | 25.0 | -20.0 | -12.5 | −41.7% |
| 2014 | 4.7 | -4.5 | -2.9 | 1.8 | -16.7 | 0.0 | 0.0 | 4.3 | -17.4 | 0.0 | -0.5 | 0.0 | −29.4% |
| 2013 | 60.0 | 0.0 | -5.0 | 0.0 | -26.3 | 21.4 | 0.0 | 0.0 | +36.0% |
No analyst coverage for this instrument.
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.